Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$159.69 USD

159.69
4,765,963

+0.16 (0.10%)

Updated Oct 8, 2024 04:00 PM ET

Pre-Market: $160.09 +0.40 (0.25%) 8:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (33 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Teleflex (TFX) Q1 Earnings Top Estimates, 2023 Sales View Up

by Zacks Equity Research

Teleflex (TFX) registers growth across the majority of its businesses, including double-digit increases in interventional and surgical revenues in Q1.

Globus Medical (GMED) Q1 Earnings Beat, Operating Margin Dips

by Zacks Equity Research

The significant year-over-year surge in Globus Medical's (GMED) Enabling Technologies sales is driven by ongoing demand for the company's robotics and imaging system technologies.

Insulet (PODD) Q1 Earnings Beat Estimates, Sales View Up

by Zacks Equity Research

Omnipod 5 continues to be a driving force of Insulet's (PODD) strong U.S. growth, representing almost 95% of U.S. new customer starts in the first quarter.

Sweta Killa headshot

ETFs to Bet on the Successful Debut of Kenvue

by Sweta Killa

Kenvue is the world's largest pure-play consumer health company by revenue, and makes well-known products, including Tylenol, Neutrogena, Listerine, Johnson¿¿¿s', Band-Aid, Aveeno, Zyrtec and Nicorette.

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Bruker (BRKR) Tops Q1 Earnings Estimates, Raises '23 Outlook

by Zacks Equity Research

Bruker (BRKR) delivers a year-over-year revenue increase across all its segments in the first quarter, led by the strong demand for differentiated, high-performance scientific instruments and life-science solutions.

Bio-Rad (BIO) Q1 Earnings Beat Estimates, Operating Margin Down

by Zacks Equity Research

Bio-Rad's (BIO) first-quarter results reflect core strength across the Life Science and Clinical Diagnostics segments amid ongoing supply-chain constraints.

Amedisys (AMED) Q1 Earnings Beat Estimates, Margins Dip

by Zacks Equity Research

Amedisys (AMED) sees a year-over-year decline in the Hospice segment's revenues.

Tandem Diabetes (TNDM) Q1 Earnings Miss, Gross Margin Dips

by Zacks Equity Research

According to Tandem Diabetes (TNDM), Q1 revenues are in line with the high end of its expectations.

FATE Incurs Narrower-Than-Expected Q1 Loss on Lower Expenses

by Zacks Equity Research

FATE reports lower-than-expected loss on higher collaboration revenues and lower operating expenses in first-quarter 2023.

Phibro (PAHC) Q3 Earnings Miss Estimates, Gross Margin Up

by Zacks Equity Research

Higher domestic demand and higher average selling prices for dairy products and growth in the companion animal product drive Phibro's (PAHC) Q3 revenues.

Envista (NVST) Q1 Earnings Miss Estimates, Margins Down

by Zacks Equity Research

Weakness in China and Russia and lower demand for large capital equipment hurts Envista's (NVST) Q1 revenues.

Qiagen (QGEN) Q1 Earnings Top Estimates, Operating Margin Down

by Zacks Equity Research

Amid an uncertain macroeconomic environment, Qiagen's (QGEN) first-quarter results reflect an impressive organic top line, led by strength in non-COVID-19 product groups.

Myriad Genetics (MYGN) Lags Q1 Earnings, Updates '23 View

by Zacks Equity Research

Myriad Genetics (MYGN) delivers a year-over-year increase in first-quarter revenues, reflecting a positive volume improvement across the portfolio.

CVS Health (CVS) Q1 Earnings Surpass Estimates, EPS View Cut

by Zacks Equity Research

CVS Health's (CVS) robust sales growth across all three operating segments drives top-line results.

DENTSPLY SIRONA (XRAY) Q1 Earnings & Revenues Beat Estimates

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) Q1 earnings and revenues decline year over year, driven by the unfavorable foreign currency movement and soft demand across all geographical segments.

Penumbra (PEN) Q1 Earnings Top Estimates, Sales Remain Robust

by Zacks Equity Research

Penumbra's (PEN) sales during the first quarter reflect continued demand for its products. The 2023 outlook is encouraging as earnings improve despite macro challenges.

Omnicell (OMCL) Q1 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Despite a year-over-year decrease, Omnicell's (OMCL) first-quarter revenues and earnings exceed the top end of the previously announced outlook amid an uncertain macroeconomic environment.

Zimmer Biomet (ZBH) Q1 Earnings Beat Estimates, View Raised

by Zacks Equity Research

Each of Zimmer Biomet's (ZBH) geographic segments and product divisions records strong year-over-year sales growth at CER.

Hologic's (HOLX) Q2 Earnings Beat Estimates, 2023 View Up

by Zacks Equity Research

The year-over-year growth in Breast Health and GYN Surgical Businesses contributed to Hologic's (HOLX) Q2 revenues.

IDEXX (IDXX) Q1 Earnings Beat Estimates, Margins Increase

by Zacks Equity Research

Continued solid demand for veterinary services and record global premium instrument placements drive IDEXX's (IDXX) Q1 revenues.

Merit Medical (MMSI) Tops Q1 Earnings Estimates, Ups FY23 View

by Zacks Equity Research

Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the first quarter.

Kinjel Shah headshot

Pharma Stock Roundup: MRK & Others Post Q1 Results, LLY Drug Shines in Obesity Study

by Kinjel Shah

Merck (MRK), Eli Lilly (LLY), AstraZeneca (AZN) and others report first-quarter results. J&J (JNJ) provides an update on the IPO of its Consumer Health segment, Kenvue.

Integer Holdings (ITGR) Q1 Earnings, Revenues Beat Estimates

by Zacks Equity Research

Integer Holdings' (ITGR) first-quarter results reflect robust Medical and Non-Medical sales, besides strength in all the product lines.

Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.